地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18771997407
邮箱:sales@amyjet.com

艾美捷科技代理Biosynth品牌。
Biosynth公司专注于碳水化合物、核苷和酶底物的化学领域;Biosynth公司在多肽领域也表现出色,涵盖从发现和优化到文库、GMP新化学实体(NCEs)和新抗原的各个环节;同时不断扩大用于生命科学研究的生物活性多肽、抗体、蛋白质、酶和试剂的产品范围。Biosynth公司定制单克隆和多克隆抗体生产,同时还提供用于诊断的关键试剂,包括病毒和细菌抗原、抗血清和血浆。Biosynth特色产品尤其推荐:生产诊断试剂用显色底物,如:5-溴-4-氯-3-吲哚显色底物、4-硝基苯基(pNP)、显色底物、4-甲基伞形酮(MU)显色底物等。
<< " data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Biosynth品牌"> 艾美捷科技代理Biosynth品牌

Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

艾美捷科技特约代理Atlas Antibodies抗体产品。
Atlas Antibodies公司开发与人类蛋白有关的抗体以及试剂,基于质谱(MS)的定量蛋白质组学,在人体中可能的20,000种蛋白质编码基因中,Atlas已经具有覆盖15,000种的基因产物,超过17,000种抗体,约13,000种蛋白质靶标。
At Atlas Antibodies we have a very clear mission: To provide our customers with advanced research reagents targeting all human proteins. The Human Protein Atlas (HPA) project released the first version of a complete tissue-based map of human protein expression using antibodies in November 2014. In close partnership with the HPA project, we continue to develop advanced antibodies and advanced reagents for Mass Spectrometry (MS)-based quantitative proteomics. Of the possible 20,000 protein coding genes in the human body we already have over 21,000 antibodies covering 15,000 gene products. Learn more in this in the video below.
Atlas Antibodies公司的主要产品包括:
Primary Antibodies
All Primary Antibodies
Triple A Polyclonals
PrecisA Monoclonals
Blocking Antigens
MS Standards
QPrESTs
Laminin Markers
Neuroscience Markers
EMT Markers
" data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Atlas Antibodies"> Atlas Antibodies
KENOSHA is the only truly specialized and independent provider of adhesive materials and related services to IVD and Medical Device manufacturers.
KENOSHA的主要产品包括:
(1)Lateral Flow
Backing Cards and Cover Tapes
Backing Cards Starter Kit
Conjugation Kits
(2)Medical Device
Medical Device Protective Packaging
Woundcare Adhesives
Filtration Media
Biosensor Films & Laminates
Medical Grade Adhesives
Microtiter Plate Sealing Tapes
IVD Trade
(3)Microfluidics
Microfluidic R2R
Paper-based Diagnostic Devices
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="KENOSHA"> KENOSHA
艾美捷科技代理Imagion Biosystems公司产品。
Imagion Biosystems公司提供高品质的PrecisionMRX®系列氧化铁(Fe3O4)纳米颗粒。PrecisionMRX®纳米颗粒是具有均匀球形形态、
窄尺寸的超顺磁性氧化铁纳米颗粒,特点是分散性和高磁弛豫性。为了达到最高质量,Imagion Biosystems使用热分解工艺,该工艺可
以精确控制纳米颗粒的尺寸、形状和磁性,并保持最小的批间差异。

Carboxylic Acid Functionalized PrecisionMRX® Nanoparticles
Size:10mg/50mg
![]()

Dextran-Coated PrecisionMRX® Nanoparticles
Size:10mg/5mg
![]()

mPEG Coated PrecisionMRX® Nanoparticles
Size:10mg/5mg
![]()

Oleic Acid Coated PrecisionMRX® Nanoparticles
Size:100mg/50mg
![]()

艾美捷科技有限公司代理Mimotopes公司多肽及多肽合成相关产品。Mimotopes公司位于澳大利亚,可以提供2000余种多肽,100余种药物及化妆品肽,1000余种各类氨基酸及多肽合成用试剂。
Mimotopes公司的主要产品类别:
(1)多肽(Peptides)
库存普通多肽(Catalogue Peptides)
化妆品肽(Cosmetic Peptides)
药物肽(Pharmaceutical Peptides)
肽库(Off-the-Shelf Library)
(2)氨基酸(Amino Acids)
Z Amino Acids
Unusual Amino Acids
N methyl Amino Acids
Fmoc Amino Acids
Common Amino Acids
Boc amino acids
AA attached_to_2-Chlorotrityl_Resin
AA attached_to_Wang_Resin
(3)多肽合成试剂(Peptides Synthesis Reagents)
Coupling Reagents
Amino Alcohols
General Reagents
Linkers
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

ProImmune公司是免疫学功能检测多聚体产品和服务的提供者。产品包括重组的MHC Class I 五聚体和MHC Class II 六聚体,用于特异性的T 细胞免疫功能检测。广泛用于传染性疾病,自身免疫学疾病和移植等热门领域的基础,新药和临床研究。
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.
ProImmune公司产品:
Pro5®MHC Class I Pentamers
CD1d Tetramers
ProT2® MHC Class II Tetramers
ProM2® MHC Class II Monomers
thinkpeptides® Peptide Products
Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Absolute Antibody重组抗体。
Absolute Antibody成立于2012年,其产品线100%专注于重组抗体。虽然重组抗体是制药行业的主流,但这些抗体尚未广泛用于诊断或研究。由于重组抗体比传统杂交瘤产生的单克隆抗体
具有许多优势,这种情况正在开始改变。
Absolute Antibody专注于抗体测序、抗体工程和抗体重组表达,并提供定制服务、重组抗体和Fc融合蛋白。Absolute Antibody的客户包括制药公司、生物技术和诊断公司,以及世界各
地的学术研究人员。此外,Absolute Antibody团队在治疗性抗体和重组表达技术领域拥有丰富的经验。自成立以来,Absolute Antibody已生产了180多种不同构型的抗体,并开发了逾
15000种重组抗体试剂。

Anogen-Yes Biotech Laboratories Ltd. 创建于1989年, 位于加拿大多伦多近郊的著名高科技城市密西沙加市。Anogen是加拿大逸士生物技术研究有限公司在国际上的市场经销部门。Anogen-Yes Biotech Laboratories Ltd.研发和生产各种新颖抗体及有关产品,应用广泛的技术平台设计和开发各种单克隆抗体、多克隆抗体、基因工程/人源化抗体、免疫检验用配对抗体、免疫球蛋白、活性多肽、酶联免疫试剂盒[ELISA]、斑点酶联免疫试剂盒[Elispots]和基因重组蛋白质等等。 这些产品主要用于生命科学研究和各种疾病的诊断和防治,包括炎症和自身免疫性疾病、心血管病和癌症等。
Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company based in Mississauga, Ontario. Founded in 1989, Anogen-Yes Biotech specializes in developing and manufacturing monoclonal antibodies, recombinant proteins, synthetic bioactive peptides, and Enzyme linked immunosorbent assay (ELISA) kits for research as well as diagnostic and therapeutic use.[1] It is also committed to seeking medical treatment of cancer, autoimmune, inflammatory and cardiovascular diseases by developing antibody-based biopharmaceuticals.
Anogen的主要产品包括:
Monoclonal Antibodies
Polyclonal Antibodies
Matched Antibody Pairs
ELISA Kits
按照研究领域细分:
Inflammatory & Growth Factors
Cell Biology & Molecular Biology
Immunoassay Reagents
Infection & Toxin
Coagulation Factors
Hormone
Neurological Disorder
Tumor Research
| 品名 | 货号 | 规格 |
| mAb anti-Human TNF-α, CH8810 | MO-C40003A | 0.1 mg |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, C2H9 | MO-C40003D | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, C2A7 | MO-C40003F | 0.1 mg |
| mAb anti-Human TNF-α, C5G7 | MO-C40003G | 0.1 mg |
| mAb anti-Human TNF-α, C4C7 | MO-C40003H | 0.1 mg |
| mAb anti-Human IFN-γ, 315 | MO-C40004D | 0.1 mg |
| mAb anti-Human IFN-γ, 165 | MO-C40004E | 0.1 mg |
| mAb anti-Human IFN-γ, 23 | MO-C40004F | 0.1 mg |
| mAb anti-Human CCR1, 293 | MO-C40005A | 0.1 mg |
| mAb anti-Human TGF-β, TB21 | MO-C40009A | 0.1 mg |
| mAb anti-Human TGF-β, 2C5 | MO-C40009B | 0.1 mg |
| mAb anti-Human TGF-β, 2C6 | MO-C40009D | 0.1 mg |
| mAb anti-Human TGF-β, 2E6 | MO-C40009E | 0.1 mg |
| mAb anti-Human TGF-β, 8C4 | MO-C40009F | 0.1 mg |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-61 | MO-C40017E | 0.1 mg |
| mAb anti-Human IL-8, 257 | MO-C40017F | 0.1 mg |
| mAb anti-Human IL-8, 807 | MO-C40017G | 0.1 mg |
| mAb anti-Human MCP-1, S8 | MO-C40021A | 0.1 mg |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, 9G10 | MO-C40021E | 0.1 mg |
| mAb anti-Human MCP-1, S382 | MO-C40021F | 0.1 mg |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 513 | MO-C40028D | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 291 | MO-C40028G | 0.1 mg |
| mAb anti-Human SAA, 504 | MO-C40028H | 0.1 mg |
| mAb anti-Human SAA, 585 | MO-C40028J | 0.1 mg |
| mAb anti-Human SAA, 426 | MO-C40028K | 0.1 mg |
| mAb anti-Human SAA, 38 | MO-C40028L | 0.1 mg |
| mAb anti-Human SAA, 132 | MO-C40028M | 0.1 mg |
| mAb anti-Human SAA, S3 | MO-C40028N | 0.1 mg |
| mAb anti-Human IL-1β, S1H12 | MO-C40029A | 0.1 mg |
| mAb anti-Human IL-1β, S1B7 | MO-C40029B | 0.1 mg |
| mAb anti-Human IL-1β, S3F12 | MO-C40029G | 0.1 mg |
| mAb anti-Human IL-1β, 464 | MO-C40029H | 0.1 mg |
| mAb anti-Human IL-2, 5A8, | MO-C40032A | 0.1 mg |
| mAb anti-Human IL-2, 9F9, | MO-C40032B | 0.1 mg |
| mAb anti-Human IL-2, 10C4 | MO-C40032C | 0.1 mg |
| mAb anti-Human IL-2, 8C2 | MO-C40032D | 0.1 mg |
| mAb anti-Human IL-2, 6F11 | MO-C40032E | 0.1 mg |
| mAb anti-Human IL-2, 6B1 | MO-C40032F | 0.1 mg |
| mAb anti-Human EGF, S-21 | MO-C40044A | 0.1 mg |
| mAb anti-Human EGF, S-120 | MO-C40044B | 0.1 mg |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-145 | MO-C40044E | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-147 | MO-C40044G | 0.1 mg |
| mAb anti-Human EGF, S-177 | MO-C40044H | 0.1 mg |
| mAb anti-Human G-CSFR, S-1252 | MO-C40045A | 0.1 mg |
| mAb anti-Human G-CSFR, S-1268 | MO-C40045B | 0.1 mg |
| mAb anti-Human G-CSFR, S-1284 | MO-C40045D | 0.1 mg |
| mAb anti-Human G-CSFR, S-1374 | MO-C40045E | 0.1 mg |
| mAb anti-Human G-CSFR, S-425 | MO-C40045F | 0.1 mg |
| mAb anti-Human G-CSFR, S-1390 | MO-C40045G | 0.1 mg |
| mAb anti-Human bFGF, F-343 | MO-C40046A | 0.1 mg |
| mAb anti-Human bFGF, F-74 | MO-C40046B | 0.1 mg |
| mAb anti-Human bFGF, F-474 | MO-C40046F | 0.1 mg |
| mAb anti-Human bFGF, F-3 | MO-C40046H | 0.1 mg |
| mAb anti-Human EPO, 85 | MO-C40047A | 0.1 mg |
| mAb anti-Human M-CSF, 116 | MO-C40048A | 0.1 mg |
| mAb anti-Human M-CSF, 692 | MO-C40048B | 0.1 mg |
| mAb anti-Human M-CSF, 21 | MO-C40048D | 0.1 mg |
| mAb anti-Human MIP-1α, 116 | MO-C40051A | 0.1 mg |
| mAb anti-Human MIP-1α, 125 | MO-C40051D | 0.1 mg |
| mAb anti-Human MIP-1α, 548 | MO-C40051F | 0.1 mg |
| mAb anti-Human MIP-1α, 199 | MO-C40051G | 0.1 mg |
| mAb anti-Human MIP-1α, 400 | MO-C40051L | 0.1 mg |
| mAb anti-Human MIP-1α, 103 | MO-C40051M | 0.1 mg |
| mAb anti-Human MIP-1α, 376 | MO-C40051N | 0.1 mg |
| mAb anti-Human MIP-1α, 426 | MO-C40051P | 0.1 mg |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 343 | MO-C40088B | 0.1 mg |
| mAb anti-Human MCP-3, 490 | MO-C40088D | 0.1 mg |
| mAb anti-Human MCP-3, 768 | MO-C40088E | 0.1 mg |
| mAb anti-Human MCP-3, 1057 | MO-C40088F | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 1015 | MO-C40088H | 0.1 mg |
| mAb anti-Human IL-16, 59 | MO-C40089G | 0.1 mg |
| mAb anti-Human IL-16, 210 | MO-C40089H | 0.1 mg |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 568 | MO-C40089M | 0.1 mg |
| mAb anti-Human IL-16, 572 | MO-C40089N | 0.1 mg |
| mAb anti-Human GM-CSF, 29 | MO-C40090A | 0.1 mg |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 204 | MO-C40090E | 0.1 mg |
| mAb anti-Human GM-CSF, 489 | MO-C40090F | 0.1 mg |
| mAb anti-Human GM-CSF, 120 | MO-C40090G | 0.1 mg |
| mAb anti-Human GM-CSF, 26 | MO-C40090H | 0.1 mg |
| mAb anti-Human GM-CSF, 174 | MO-C40090K | 0.1 mg |
| mAb anti-Human GM-CSF, S333 | MO-C40090L | 0.1 mg |
| mAb anti-Human IL-6, 2E10 | MO-C40091B | 0.1 mg |
| mAb anti-Human IL-6, 8E10 | MO-C40091C | 0.1 mg |
| mAb anti-Human IL-6, 5G8 | MO-C40091D | 0.1 mg |
| mAb anti-Human IL-6, 1B6 | MO-C40091E | 0.1 mg |
| mAb anti-Human IL-6, 1E3 | MO-C40091F | 0.1 mg |
| mAb anti-Human IL-6, 6D7 | MO-C40091G | 0.1 mg |
| mAb anti-Human IL-6, 9D8 | MO-C40091H | 0.1 mg |
| mAb anti-Human IL-10, 4H2 | MO-C40092A | 0.1 mg |
| mAb anti-Human IL-10, 6D2 | MO-C40092B | 0.1 mg |
| mAb anti Human IL-17A clone 4C1, Capture | MO-C40093A | 0.1mg |
| mAb anti Human IL-17A clone 2F3 | MO-C40093B | 0.1mg |
| mAb anti Human IL-17A clone 8H7 | MO-C40093C | 0.1mg |
| mAb anti Human IL-17A clone 5B4 | MO-C40093D | 0.1mg |
| mAb anti Human IL-17A clone 1E2 | MO-C40093E | 0.1mg |
| mAb anti Human IL-17A clone 2D11 | MO-C40093H | 0.1mg |
| mAb anti Human IL-17A clone 3C1 | MO-C40093I | 0.1mg |
| mAb anti Human IL-17A clone 3H11, Detector | MO-C40093K | 0.1mg |
| mAb anti Human IL-17A clone 5A9 | MO-C40093M | 0.1mg |
| mAb anti Human IL-17A clone 6F12 | MO-C40093O | 0.1mg |
| mAb anti Human IL-17A clone 7F10 | MO-C40093S | 0.1mg |
| mAb anti Human IL-17A clone 10F9 | MO-C40093W | 0.1mg |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti-human LIF, Clone 2C6 | MO-C40096A | 0.1mg |
| mAb anti-human LIF, Clone 3F4 | MO-C40096B | 0.1mg |
| mAb anti-human LIF, Clone 8B10 | MO-C40096C | 0.1mg |
| mAb anti-DYKDDDDK (Flag) Tag, Flag.10F4 | MO-H40001B | 0.1 mg |
| mAb anti-GAPDH, H8 | MO-H40002A | 0.1 mg |
| mAb anti-HA Tag, HA52 | MO-H40004A | 0.1 mg |
| mAb anti-His Tag, 10A12 | MO-H40005B | 0.1 mg |
| mAb anti-Myc Tag, MycA7 | MO-H40006A | 0.1 mg |
| mAb anti-V5 Tag, V531 | MO-H40007A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 163 | MO-I40002C | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 587, 0.1 mg | MO-I40002E | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 425 | MO-I40002I | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 1027 | MO-I40002J | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 287 | MO-I40002N | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 161 | MO-I40002P | 0.1 mg |
| mAb anti-HBsAg, RM-1 | MO-I40013A | 0.1 mg |
| mAb anti-HCV Core Protein, A1/3D1 | MO-I40015A | 0.1 mg |
| mAb anti-HCV Core Protein, B2 | MO-I40015B | 0.1 mg |
| mAb anti-HCV Core Protein, C3 | MO-I40015E | 0.1 mg |
| mAb anti-HCV NS-4, 7B7/5G9 | MO-I40016B | 0.1 mg |
| mAb anti-HCV NS-4, 5D4/10E7 | MO-I40016D | 0.1 mg |
| mAb anti-HCV NS-4, 7E11 | MO-I40016F | 0.1 mg |
| mAb anti-HCV NS-4, 202 | MO-I40016J | 0.1 mg |
| mAb anti-HCV NS-4, 101 | MO-I40016K | 0.1 mg |
| mAb anti-HCV NS-4, 174 | MO-I40016L | 0.1 mg |
| mAb anti-HCV NS-4, 497 | MO-I40016M | 0.1 mg |
| mAb anti-HCV NS-3, 70-13 | MO-I40018A | 0.1 mg |
| mAb anti-HCV NS-3, 1-5 | MO-I40018B | 0.1 mg |
| mAb anti-HCV NS-3, 12-15 | MO-I40018D | 0.1 mg |
| mAb anti-HCV NS-3, 5-11 | MO-I40018E | 0.1 mg |
| mAb anti-HCV NS-3, 24-8 | MO-I40018F | 0.1 mg |
| mAb anti-HCV NS-3, 20-8 | MO-I40018G | 0.1 mg |
| mAb anti-HCV NS-3, 113 | MO-I40018H | 0.1 mg |
| mAb anti-HCV NS-3, 281 | MO-I40018J | 0.1 mg |
| mAb anti-HCV NS-3, 806 | MO-I40018K | 0.1 mg |
| mAb anti-HCV NS-3, 5 | MO-I40018L | 0.1 mg |
| mAb anti-HCV NS-3, 328 | MO-I40018M | 0.1 mg |
| mAb anti-HCV NS-3, 251 | MO-I40018N | 0.1 mg |
| mAb anti-HCV NS-3, 242 | MO-I40018P | 0.1 mg |
| mAb anti-HCV NS-3, 133 | MO-I40018Q | 0.1 mg |
| mAb anti-HEV, S-13 | MO-I40019B | 0.1 mg |
| mAb anti-HEV, 4H5 | MO-I40019C | 0.1 mg |
| mAb anti-HEV, 2H6 | MO-I40019D | 0.1 mg |
| mAb anti-HEV, 2H2 | MO-I40019E | 0.1 mg |
| mAb anti-HEV, 1B6 | MO-I40019F | 0.1 mg |
| mAb anti-HEV, 5H4 | MO-I40019G | 0.1 mg |
| mAb anti-HP CagA, 10E9, | MO-I40020A | 0.1 mg |
| mAb anti-HP CagA, 5H10 | MO-I40020B | 0.1 mg |
| mAb anti-HP CagA, 5C6 | MO-I40020C | 0.1 mg |
| mAb anti-HP CagA, 3C10, | MO-I40020D | 0.1 mg |
| mAb anti-HP CagA, 3C1 | MO-I40020E | 0.1 mg |
| mAb anti-TB 38KD Antigen, D2G2 | MO-I40021A | 0.1 mg |
| mAb anti-TB 38KD Antigen, C12H11 | MO-I40021B | 0.1 mg |
| mAb anti-TB 38KD Antigen, C11B10 | MO-I40021C | 0.1 mg |
| mAb anti-TB 38KD Antigen, B12F8 | MO-I40021D | 0.1 mg |
| mAb anti-TB 38KD Antigen, A11D2 | MO-I40021E | 0.1 mg |
| mAb anti-TB 38KD Antigen, A2H8 | MO-I40021F | 0.1 mg |
| mAb anti-Human CD3, JXT3 | MO-L40001A | 0.1 mg |
| Rat anti-Mouse CD4, JXYT4 | MO-L40026 | 0.1 mg |
| Rat anti-Mouse CD8, JXYT8 | MO-L40027 | 0.1 mg |
| mAb anti-Human CD11α, A11 | MO-L40028 | 0.1 mg |
| mAb anti-Human HLA-ABC, LY5.1 | MO-L40033 | 0.1 mg |
| mAb anti-Human CD71 Transferrin Receptor, CY-TFR | MO-L40042 | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 1C4 | MO-L40043A | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7C9, Capture | MO-L40043B | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9E11 | MO-L40043E | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9B4 | MO-L40043F | 0.1 mg |
| mAb anti-Human PD-1 / CD279, B1C4 | MO-L40043G | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7G12, Detector | MO-L40043L | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 2H7 | MO-L40043M | 0.1 mg |
| mAb anti Human PD-L1, clone 6A5 | MO-L40044E | 0.1 mg |
| mAb anti Human PD-L1 clone 8C12 | MO-L40044F | 0.1 mg |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 11D11 | MO-L40044M | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti Human PD-L1 clone 12D9 | MO-L40044O | 0.1 mg |
| mAb anti Human PD-L1 clone 15F2 | MO-L40044R | 0.1 mg |
| mAb anti Human PD-L1, clone 10B12 | MO-L40044S | 0.1 mg |
| mAb anti Human CD47, clone 1G10 | MO-L40045A | 0.1 mg |
| mAb anti Human CD47, clone 8H7 | MO-L40045B | 0.1 mg |
| mAb anti Human CD47, clone 9F10 | MO-L40045C | 0.1 mg |
| mAb anti Human CD44, clone 2G7 | MO-L40046A | 0.1 mg |
| mAb anti Human CD44, clone 3C7 | MO-L40046B | 0.1 mg |
| mAb anti-hCG-α, CH5 | MO-M40010A | 0.1 mg |
| mAb anti-hCG-α, CH7 | MO-M40010B | 0.1 mg |
| mAb anti-TRICHOSANTHIN (TCST), TCST-1, 0.1 mg | MO-M40011A | 0.1 mg |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-Human Ig Kappa Light Chain, YCK1 | MO-M40020 | 0.1 mg |
| mAb anti-Human B2MG, D6E4 | MO-M40021B | 0.1 mg |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D6D1 | MO-M40021D | 0.1 mg |
| mAb anti-Human B2MG, D2A10 | MO-M40021E | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human CRP, 67A1 | MO-M40023B | 0.1 mg |
| mAb anti-human CRP, N1G1 | MO-M40023D | 0.1 mg |
| mAb anti-human CRP, S5G1 | MO-M40023E | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1C6, 0.1 mg | MO-M40025A | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1E6, 0.1 mg | MO-M40025B | 0.1 mg |
| mAb Rat anti-Aflatoxin, 2E4 | MO-M40025D | 0.1 mg |
| mAb anti-Human Albumin, S4D6 | MO-M40036 | 0.1 mg |
| mAb anti-Human Factor IX, F9-1, .01 mg | MO-M40037 | 0.1 mg |
| mAb anti-Human Protein C, HLW-C, 0.1 mg | MO-M40038 | 0.1 mg |
| mAb anti-Human Factor X, F10-1, 0.1 mg | MO-M40039 | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 237, 0.1 mg | MO-M40040A | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 474, 0.1 mg | MO-M40040B | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, Y8 | MO-M40040D | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 700 | MO-M40040E | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 585 | MO-M40040F | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 8 | MO-M40040H | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 291 | MO-M40040J | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 262 | MO-M40040N | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 71 | MO-M40040Q | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 128 | MO-M40040S | 0.1 mg |
| mAb anti-Staphylococcal Enterotoxin B [SEB], 0.1 mg | MO-M40041 | 0.1 mg |
| mAb anti-Human PTP1-C, PTY6 | MO-M40043A | 0.1 mg |
| mAb anti-Human PTP1-C, PTY11 | MO-M40043B | 0.1 mg |
| mAb anti-Human PTP1-C, PTY15 | MO-M40043D | 0.1 mg |
| mAb anti-Human PTP1-C, PTY10 | MO-M40043E | 0.1 mg |
| mAb anti-Human PTP1-C, PTY13 | MO-M40043F | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human Raf-1, 410 | MO-M40091E | 0.5 mg |
| mAb anti-Human Raf-1, 540 | MO-M40091G | 0.5 mg |
| mAb anti-Human Raf-1, 863 | MO-M40091J | 0.5 mg |
| mAb anti-Human Raf-1, 163 | MO-M40091M | 0.5 mg |
| mAb anti-Human NSE, 145 | MO-M40092A | 0.5 mg |
| mAb anti-Human NSE, 1G6 | MO-M40092B | 0.5 mg |
| mAb anti-Human NSE, 171 | MO-M40092C | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3B3 | MO-M40093A | 0.1 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3F8 | MO-M40093D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 3F5 | MO-M40094A | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1H3 | MO-M40094B | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 6C8 | MO-M40094C | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4A2 | MO-M40094E | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7H7 | MO-M40094F | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5A4 | MO-M40094G | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4B7 | MO-M40094H | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7G10 | MO-M40094I | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1F10 | MO-M40094J | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 8B2 | MO-M40095B | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, 4B1 | MO-M40095C | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 5G5 | MO-M40096A | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 9F2 | MO-M40096B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4H11 | MO-M40097A | 0.1 mg |
| mAb anti-Human α-Synuclein, 4C1 | MO-M40097B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4B4 | MO-M40097C | 0.1 mg |
| mAb anti-Human α-Synuclein, 8F12 | MO-M40097D | 0.1 mg |
| mAb anti-Human α-Synuclein, 9A9 | MO-M40097E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, 3E11 | MO-M40098A | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B2B3 | MO-M40098B | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B4H12 | MO-M40098C | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B5B11 | MO-M40098D | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7B10 | MO-M40098E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7H2 | MO-M40098F | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 1A4 | MO-M40099A | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 7G9 | MO-M40099B | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 9B4 | MO-M40099C | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 2A4 | MO-M40099D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 8E1 | MO-M40100A | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 1G8 | MO-M40100B | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4C1 | MO-M40100C | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 3B12 | MO-M40100D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H1 | MO-M40100E | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H11 | MO-M40100F | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 5C11 | MO-M40100G | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 10G9 | MO-M40100H | 0.1 mg |
| mAb anti-LCRMP4, 5H5 | MO-M40101A | / |
| mAb anti-LCRMP4, 2H7 | MO-M40101B | / |
| mAb anti-LCRMP4 , 7E1 | MO-M40101C | / |
| mAb anti-Human Phospho-STAT5b [p-Y699], A4B9 | MO-P40001A | 0.1 mg |
| mAb anti-Human Phospho-STAT5b [p-Y699], A2H6 | MO-P40001B | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], B4A12 | MO-P40002A | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], D7H2 | MO-P40002B | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], A3A4 | MO-P40003A | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], B1C4 | MO-P40003B | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, C4F9 | MO-P40006A | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, B4D9B10 | MO-P40006B | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, 3D7 | MO-P40007A | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, B7H10 | MO-P40007B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, CHALU2 | MO-T40005B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, 3504 | MO-T40005C | 0.1 mg |
| mAb anti-Human Hepatocellular Carcinoma, CHALV1 | MO-T40006A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human BPH, YBPH-1 | MO-T40008A | 0.1 mg |
| mAb anti-Human BPH, YBPH-2 | MO-T40008B | 0.1 mg |
| mAb anti-Human PML, B3E9 | MO-T40010A | 0.1 mg |
| mAb anti-Human PML, B4C8 | MO-T40010B | 0.1 mg |
| mAb anti-CA 125, 110 | MO-T40012A | 0.1 mg |
| mAb anti-CA 125, 76 | MO-T40012B | 0.1 mg |
| mAb anti-CA 125, 23 | MO-T40012C | 0.1 mg |
| mAb anti-CA 125, 15 | MO-T40012D | 0.1 mg |
| mAb anti-CA 125 | MO-T40012E | 0.1 mg |
| mAb anti-CA50, 93 | MO-T40014A | 0.1 mg |
| mAb anti-CA50, 826 | MO-T40014B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,8E2 (Free Sample Available) | MO-T40015A | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9B2 (Free Sample Available) | MO-T40015B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,1A5 (Free Sample Available) | MO-T40015C | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,4E11 (Free Sample Available) | MO-T40015D | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9E1 (Free Sample Available) | MO-T40015E | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7C4 (Free Sample Available) | MO-T40015F | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7E6 (Free Sample Available) | MO-T40015G | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma, Y94 | MO-T40022 | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma/CD3, BS-1 | MO-T40035 | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PMA, YPMA-1 | MO-T40083A | 0.1 mg |
| mAb anti-Human PMA, YPMA-2 | MO-T40083B | 0.1 mg |
| mAb anti-Human PSP, YPSP-1 | MO-T40085A | 0.1 mg |
| mAb anti-Human PSP, YPSP-2 | MO-T40085B | 0.1 mg |
| mAb anti-Human PSP, YPSP-3 | MO-T40085C | 0.1 mg |
| mAb anti-Human PSP, YPSP-4 | MO-T40085D | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-1 | MO-T40086A | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-2 | MO-T40086B | 0.1 mg |
| mAb anti-Human PSMA, 4H11 | MO-T40086C | 0.1 mg |
| mAb anti-Human PSMA, 7F3 | MO-T40086D | 0.1 mg |
| mAb anti-Human PTMA, 8H12 | MO-T40087A | 0.1 mg |
| mAb anti-Human PTMA, 9A10 | MO-T40087B | 0.1 mg |
| mAb anti-Human PTMA, 6A3 | MO-T40087C | 0.1 mg |
| mAb anti-Human PTMA, 4G2 | MO-T40087D | 0.1 mg |
| mAb anti-Human PTMA, 5A10 | MO-T40087E | 0.1 mg |
| mAb anti-Human PTMA, 6H7 | MO-T40087F | 0.1 mg |
| mAb anti-Human PTMA, 1F2, Capture | MO-T40087G | 0.1 mg |
| mAb anti-Human PTMA, 4C3 | MO-T40087H | 0.1 mg |
| mAb anti-Human PTMA, 4A7, Detector | MO-T40087I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9A4 | MO-T40088A | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E6 | MO-T40088B | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 1A10 | MO-T40088C | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5C2 | MO-T40088D | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 10H9 | MO-T40088E | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2A3 | MO-T40088F | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E5 | MO-T40088G | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5H12 | MO-T40088H | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9C7 | MO-T40088I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9D5 | MO-T40088J | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 3E7 | MO-T40088K | 0.1 mg |
| Human PSA ELISA Kit | EL10005 | 96 wells |
| Human IL-8 ELISA Kit | EL10008 | 96 wells |
| Human MCAF / MCP-1 ELISA Kit | EL10009 | 96 wells |
| Human EGF ELISA Kit | EL10010 | 96 wells |
| Human LH ELISA Kit | EL10011 | 96 wells |
| Human TSH ELISA Kit | EL10012 | 96 wells |
| Neonatal TSH ELISA Kit | EL10012N | 96 wells |
| Ultra-Sensitive Human TSH ELISA Kit | EL10012U | 96 wells |
| Human FSH ELISA Kit | EL10013 | 96 wells |
| Human Prolactin ELISA Kit | EL10014 | 96 wells |
| Human SAA ELISA Kit | EL10015 | 96 wells |
| Human SAA ELISA Kit (2nd Generation) | EL10015L | 96 wells |
| Human MCP-3 ELISA Kit | EL10016 | 96 wells |
| Human TNF-α ELISA Kit | EL10019 | 96 wells |
| Human GM-CSF ELISA Kit | EL10020 | 96 wells |
| Human IL-16 ELISA Kit | EL10021 | 96 wells |
| High Sensitivity Human CRP ELISA Kit | EL10022hs | 96 wells |
| Human IL-6 ELISA Kit | EL10023 | 96 wells |
| Human IFN-γ ELISA Kit | EL10024 | 96 wells |
| Human IL-2 ELISA Kit | EL10025 | 96 wells |
| Human IL-4 ELISA Kit | EL10026 | 96 wells |
| Human IL-10 ELISA Kit | EL10027 | 96 wells |
| Human IL-1β ELISA Kit | EL10028 | 96 wells |
| Human TGF-β1 ELISA Kit | EL10029 | 96 wells |
| Human Growth Hormone (hGH) ELISA Kit/Hormone Elisa | EL10030 | 96 wells |
| High Sensitivity Human Growth Hormone (H-hGH) ELISA Kit | EL10030H | 96 wells |
| Human Chorionic Gonadotropin (hCG) ELISA Kit | EL10031 | 96 wells |
| Human IL-12 (P70) ELISA Kit | EL10032 | 96 wells |
| Human IL-2 sRα ELISA Kit | EL10033 | 96 wells |
| Human IL-6 sR ELISA Kit | EL10034 | 96 wells |
| Human IL-5 ELISA Kit | EL10035 | 96 wells |
| HAMA ELISA Kit | EL10036 | 96 wells |
| Human IL-13 Rα2 ELISA Kit | EL10039 | 96 wells |
| Human IL-1α ELISA Kit | EL10040 | 96 wells |
| Human IL-7 ELISA Kit | EL10041 | 96 wells |
| Human IL-11 ELISA Kit | EL10042 | 96 wells |
| Human IL-15 ELISA Kit | EL10044 | 96 wells |
| Human M-CSF ELISA Kit | EL10046 | 96 wells |
| Human TNF-β ELISA Kit | EL10047 | 96 wells |
| Human bFGF ELISA Kit | EL10048 | 96 wells |
| Human Alphafetoprotein (AFP) ELISA Kit | EL10049 | 96 wells |
| Human B2MG ELISA Kit | EL10051 | 96 wells |
| Human Carcinoembryonic Antigen (CEA) ELISA Kit | EL10052 | 96 wells |
| Human IL-17A ELISA Kit | EL10053 | 96 wells |
| Human IL-13 ELISA Kit | EL10054 | 96 wells |
| Human IL-22 ELISA Kit | EL10055 | 96 wells |
| Human IL-9 ELISA Kit | EL10056 | 96 wells |
| Human Amyloid Beta Peptide 42 ELISA Kit | EL10057 | 96 wells |
| Human Programmed Death-Ligand 1 (PD-L1) ELISA Kit | EL10058 | 96 wells |
| Human Programmed Death-1 (PD-1) ELISA Kit | EL10059 | 96 wells |
| Human IL-18 ELISA Kit | EL10060 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Inflammatory) | EM10001 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines) | EM10002 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17) | EM10003 | 96 wells |
| Mouse IL-17A ELISA Kit | MEC1001 | 96 wells |
| Mouse IFN-γ ELISA Kit | MEC1002 | 96 wells |
| Mouse TNF-α ELISA Kit | MEC1003 | 96 wells |
| Mouse GM-CSF ELISA Kit | MEC1004 | 96 wells |
| Mouse MCP-1 ELISA Kit | MEC1005 | 96 wells |
| Mouse IL-2 ELISA Kit | MEC1006 | 96 wells |
| Mouse IL-5 ELISA Kit | MEC1007 | 96 wells |
| Mouse IL-6 ELISA Kit | MEC1008 | 96 wells |
| Mouse IL-4 ELISA Kit | MEC1009 | 96 wells |
| Mouse IL-1β ELISA Kit | MEC1010 | 96 wells |
| Mouse IL-1α ELISA Kit | MEC1011 | 96 wells |
| Mouse TGF-β1 ELISA Kit | MEC1012 | 96 wells |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Tracer (HRP Labeled) | MO-C40003T | 0.2 mL |
| mAb anti-Human TNF-α, B1E4, Tracer (Biotin Labeled) | MO-C40003TB | 0.1 mL |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Tracer (HRP Labeled) | MO-C40017T | 0.2 mL |
| mAb anti-Human IL-8, I8-60, Tracer (Biotin Labeled) | MO-C40017TB | 0.1 mL |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, S101, Tracer (HRP Labeled) | MO-C40021T | 0.2 mL |
| mAb anti-Human MCP-1, S101, Tracer (Biotin Labeled) | MO-C40021TB | 0.1 mL |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 607, Tracer (HRP Labeled), 0.2mL | MO-C40028T | 0.2 mL |
| mAb anti-Human SAA, 607, Tracer (Biotin Labeled), 0.1mL | MO-C40028TB | 0.1 mL |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-146, Tracer (HRP Labeled) | MO-C40044T | 0.2 mL |
| mAb anti-Human EGF, S-146, Tracer (Biotin Labeled) | MO-C40044TB | 0.1 mL |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 113, Tracer (HRP Labeled) | MO-C40088T | 0.2 mL |
| mAb anti-Human MCP-3, 113, Tracer (Biotin Labeled) | MO-C40088TB | 0.1 mL |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 323, Tracer (HRP Labeled) | MO-C40089T | 0.2 mL |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Tracer (HRP Labeled) | MO-C40090T | 0.2 mL |
| mAb anti-Human GM-CSF, 429, Tracer (Biotin Labeled) | MO-C40090TB | 0.1 mL |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti human IL-15 clone B1H6, Tracer (Biotin labeled) | MO-C40095TB | 0.1 mL |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Tracer (HRP), 0.2 mL | MO-I40002T2 | 0.2 mL |
| mAb anti-Human PD-1 / CD279, 7G12, Tracer (Biotin labeled) | MO-L40043TB | 0.1 mL |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti human PD-L1 clone 12B4, Tracer (Biotin Labeled) | MO-L40044TB | 0.1 mL |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-hGH, YC8, Tracer (HRP Labeled), 0.2 mL | MO-M40012T | 0.2 mL |
| mAb anti-hGH, YC8, Tracer (Biotin Labeled), 0.1 mL | MO-M40012TB | 0.1 mL |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Tracer (HRP Labeled), 0.2mL | MO-M40021T | 0.2 mL |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-human TSH, TSH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40046T | 0.2 mL |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human Prolactin, PRL-2, Tracer (HRP Labeled), 0.2 mL | MO-M40047T | 0.2 mL |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-Human LH, LH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40048T | 0.2 mL |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-hCG, HCG-2, Tracer (HRP Labeled), 0.2 mL | MO-M40049T | 0.2 mL |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human FSH, FSH-2, Tracer (HRP Labeled) | MO-M40050T | 0.2 mL |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Tracer (Biotin) | MO-M40093TB | 0.1 mL |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Tracer (Biotin) | MO-M40095TB | 0.1 mL |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human AFP, AFP-2, Tracer (HRP Labeled), 0.2 mL | MO-T40007T | 0.2 mL |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Tracer (HRP Labeled), 0.2 mL | MO-T40051T | 0.2 mL |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Tracer (HRP Labeled), 0.2 mL | MO-T40052T | 0.2 mL |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Tracer (HRP Labeled), 0.2 mL | MO-T40081T | 0.2 mL |
| Human Chorionic Gonadotrophin (hCG), 10 mg | AP30002 | 10 mg |
| Human Immunoglobulin G (IgG), 10 mg | IG30001 | 10 mg |
| Mouse Immunoglobulin G (IgG), 10 mg | IG41002 | 10 mg |
| Mouse Immunoglobulin G2b (IgG2b), 10 mg | IG41004 | 10 mg |
| Rat Immunoglobulin G (IgG) | IG42003 | 10 mg |
| Human Umbilical Cord Serum, 10 mL | S30010 | 10 mL |
| ELISA Coating (EC) Stabilizer, 500 mL | S7001 | 500 mL |
| Human IL-8 Matched Antibody Pair for ELISpot | SL10008A | 5 × 96 wells |
| Human IL-8 Development Set for ELISpot | SL10008B | 5 × 96 wells |
| Human IL-8 ELISpot Kit | SL10008E | 6 X 96 wells |
| Human MCAF (MCP-1) Matched Antibody Pair for ELISpot | SL10009A | 5 × 96 wells |
| Human MCAF (MCP-1) Development Set for ELISpot | SL10009B | 5 × 96 wells |
| Human MCAF (MCP-1) ELISpot Kit | SL10009E | 6 X 96 wells |
| Human GM-CSF Matched Antibody Pair for ELISpot | SL10020A | 5 × 96 wells |
| Human GM-CSF Development Set for ELISpot | SL10020B | 5 × 96 wells |
| Human GM-CSF ELISpot Kit | SL10020E | 6 X 96 wells |
| Human IFN-γ Matched Antibody Pair for ELISpot | SL10024A | 5 × 96 wells |
| Human IFN-γ Development Set for ELISpot | SL10024B | 5 × 96 wells |
| Human IFN-γ ELISpot Kit | SL10024E | 6 X 96 wells |
| Human IL-12 (P70) ELISpot Kit | SL10032E | 6 X 96 wells |
| TMB Solution (500 mL Part A & 500 mL Part B) | SU6006 | 1.0 L |
| pAb Rabbit anti-HCV Virus, 1.0 mg | AI20006P | 1.0 mg |
| pAb Rabbit anti-HIV-1 p24, 1.0 mg | AI20008P | 1.0 mg |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| pAb Rabbit anti-Mouse IgG , 1.0 mg | AI50005 | 1.0 mg |
| pAb Rabbit anti-Mouse IgG - HRP Conjugated, 1.0 mL | AI50005P | 1.0 mL |
| pAb Rabbit anti-hGH, | AI50006P | 1.0 mg |
| pAb Chicken anti-human IL-8 (IgY fraction) | AI60001 | 1.0 mg |
| pAb Rabbit anti-Human FPRL-1 2nd Extracellular Loop | AI70001A | 0.1 mg |
| pAb Rabbit anti-Human FPRL-1 C-terminal | AI70001B | 0.1 mg |
| pAb Rabbit anti-Human PML [Ring Finger Domain] | AI70002A | 0.1 mg |
| pAb Rabbit anti-Human PML [B-box 1 domain] | AI70002B | 0.1 mg |
| pAb Rabbit anti-Bcl-2 | AI70003A | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-2 (Thr56) | AI70003B | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-xL (Thr115) | AI70003D | 0.1 mg |
| pAb Rabbit anti-Phospho c-kit (Tyr719) | AI70004A | 0.1 mg |
| pAb Rabbit anti-Phospho IKK-γ (Ser31) | AI70005A | 0.1 mg |
| pAb Rabbit anti-NF-κB-p65 (RelA) | AI70006A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser276) | AI70007A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser468) | AI70008A | 0.1 mg |
| pAb Rabbit anti-Phospho NF-қB-p105/p50 (Ser337) | AI70009A | 0.1 mg |
| pAb Rabbit anti-Human Serum Albumin (HSA) | AI80001 | 0.1 mg |
| pAb Rabbit anti-Human Fibrinogen, 0.1 mg | AI80002 | 0.1 mg |
| pAb Rabbit anti-Human Transferrin | AI80003 | 0.1 mg |
| pAb Rabbit anti-Human IgA, 0.5 mg | AI80004 | 0.5 mg |
| pAb Rabbit anti-human IgM, 0.5 mg | AI80005 | 0.5 mg |
| pAb Rabbit anti-Human TREK-1 (K2p2.1) | AI80006A | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip1 | AI80007 | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip4 | AI80008 | 0.1 mg |
| pAb Rabbit anti-Mouse Kv4.3 | AI80010A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV1 | AI80011A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV3 | AI80012A | 0.1 mg |
| pAb Rabbit anti-Human JAK2 | AI80013A | 0.1 mg |
| pAb Rabbit anti-Human Glutathione S Transferase (GST), 0.1 mg | AI80014 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 42 | AI90001 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 43 | AI90002 | 0.1 mg |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://synaptic.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18995651644
传真:18372041646
邮箱:sales@amyjet.com
0.386